Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by equities research analysts at Nomura from a “neutral” rating to a “buy” rating in a research note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm currently has a $323.00 target price on the stock. Nomura’s price objective would indicate a potential upside of 34.28% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 14th. They set a “buy” rating and a $395.00 price target on the stock. Separately, analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, July 2nd. They set a “neutral” rating and a $265.00 price target on the stock. Finally, analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, June 30th. They set an “outperform” rating and a $425.00 price target on the stock. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $454.20.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 240.55 on Tuesday. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock’s 50-day moving average is $244.0 and its 200-day moving average is $296.. The company’s market cap is $5.072 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-14.82 earnings per share for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.